As we illustrated in network pharmacologic analysis (Fig 6), these compounds might work in combination with other active compounds to attenuate obesity via modulating major targets including PTGS2, ADRB2, and NCOA2. This evidence concerns the gene PTGS2 and obesity due to melanocortin 4 receptor deficiency.